The Quest Diagnostics Incorporated line shows up 31 times in the congressional disclosure record between 2015 and 2026, filed by 10 members: 20 purchases against 11 sales. On balance the chamber has been net buyers, and the purchases sit up 27.2% against the latest close.
*Purchases only, weighted by the midpoint of each disclosed dollar band and marked to the latest close. Filings report a range, never a share count, so this follows the stock rather than anyone's position size.
Reported a DGX purchase in filings from the last 90 days, newest first. 1 member.
Members ranked by how their reported DGX purchases have moved since, over roughly the last three years, weighted by disclosed band midpoint and marked to the latest close.
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2026-09-04 | Rohit Khanna | BUY | $1K–$15K | $237.14 | $242.95 2026-10-26 | +2.5% |
| 2026-03-30 | Alan Armstrong | BUY | $1K–$15K | $197.16 | $237.14 2026-09-04 | +20.3% |
| 2026-03-27 | Alan Armstrong | BUY | $1K–$15K | $195.51 | $237.14 2026-09-04 | +21.3% |
| 2025-10-30 | Julie Johnson | SELL | $1K–$15K | $175.75 | $237.14 2026-09-04 | -34.9% exit |
| 2025-10-30 | Julie Johnson | BUY | $1K–$15K | $175.75 | $237.14 2026-09-04 | +34.9% |
| 2025-03-10 | Carol Devine Miller | SELL | $15K–$50K | $173.12 | $237.14 2026-09-04 | -37.0% exit |
| 2025-03-10 | Carol Devine Miller | SELL | $1K–$15K | $173.12 | $237.14 2026-09-04 | -37.0% exit |
| 2025-01-17 | Rohit Khanna | BUY | $1K–$15K | $151.20 | $237.14 2026-09-04 | +56.8% |
| 2024-04-04 | Earl Blumenauer | SELL | $1K–$15K | $131.50 | $237.14 2026-09-04 | -80.3% exit |
| 2024-01-03 | Thomas H Tuberville | SELL | $15K–$50K | $139.68 | $237.14 2026-09-04 | -69.8% exit |
| 2023-12-11 | Thomas R Carper | SELL | $1K–$15K | $136.94 | $237.14 2026-09-04 | -73.2% exit |
| 2022-11-14 | Carol Devine Miller | BUY | $1K–$15K | $150.38 | $237.14 2026-09-04 | +57.7% |
| 2021-07-28 | Carol Devine Miller | BUY | $15K–$50K | $139.97 | $237.14 2026-09-04 | +69.4% |
| 2021-03-29 | Thomas H Tuberville | BUY | $1K–$15K | $128.04 | $237.14 2026-09-04 | +85.2% |
| 2020-06-01 | Dean Phillips | SELL | $1K–$15K | $118.44 | $237.14 2026-09-04 | -100.2% exit |
| 2020-04-02 | Thomas R Carper | BUY | $1K–$15K | $77.45 | $237.14 2026-09-04 | +206.2% |
| 2020-04-02 | Thomas R Carper | BUY | $1K–$15K | $77.45 | $237.14 2026-09-04 | +206.2% |
| 2020-03-02 | Earl Blumenauer | BUY | $1K–$15K | $112.11 | $237.14 2026-09-04 | +111.5% |
| 2020-01-21 | Michael T. McCaul | BUY | $15K–$50K | $107.34 | $237.14 2026-09-04 | +120.9% |
| 2020-01-21 | Michael T. McCaul | BUY | $1K–$15K | $107.34 | $237.14 2026-09-04 | +120.9% |
| 2020-01-14 | Michael T. McCaul | BUY | $15K–$50K | $106.50 | $237.14 2026-09-04 | +122.7% |
| 2020-01-14 | Michael T. McCaul | BUY | $1K–$15K | $106.50 | $237.14 2026-09-04 | +122.7% |
| 2019-07-31 | Dean Phillips | BUY | $1K–$15K | $102.08 | $237.14 2026-09-04 | +132.3% |
| 2019-05-07 | Michael T. McCaul | BUY | $1K–$15K | $97.67 | $237.14 2026-09-04 | +142.8% |
| 2019-05-07 | Michael T. McCaul | BUY | $1K–$15K | $97.67 | $237.14 2026-09-04 | +142.8% |
| 2019-04-04 | Dean Phillips | SELL | $1K–$15K | $91.02 | $242.95 2026-10-26 | -166.9% exit |
| 2019-02-04 | Dean Phillips | BUY | $1K–$15K | $87.93 | $237.14 2026-09-04 | +169.7% |
| 2018-01-02 | Rohit Khanna | SELL | $1K–$15K | $98.90 | $237.14 2026-09-04 | -139.8% exit |
| 2017-11-30 | Rohit Khanna | BUY | $1K–$15K | $98.46 | $237.14 2026-09-04 | +140.8% |
| 2016-06-20 | Lois Frankel | SELL | $1K–$15K | $77.84 | $237.14 2026-09-04 | -204.7% exit |
| 2015-05-27 | Lois Frankel | SELL | $1K–$15K | $77.16 | $242.95 2026-10-26 | -214.9% exit |
Buys are marked to the latest close and treated as open. A sell tagged rt closes an earlier disclosed buy in the same name. exit shows how the stock moved after the member sold.
10 members of the U.S. House and Senate have disclosed Quest Diagnostics Incorporated transactions under the STOCK Act — 20 purchases and 11 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
1 member disclosed a DGX purchase in the last 90 days — most recently Rohit Khanna on 2026-09-04. See the "Lawmakers who bought DGX recently" section above for the dated list.
Notional-weighted, lawmakers' disclosed DGX buys are up 27.2% versus the latest close of $242.95. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded DGX and how it performed.